GI Malignancy

  • Irene ChongEmail author
  • Diana Tait
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


GI malignancy covers four main tumour sites: oesophagogastric, hepatobiliary, colorectal and anus with radiotherapy having an important role to play in each of these sites. PET-CT is not standard in the planning procedure for these patients, but research is ongoing and most available data relates to rectal cancer [1, 2].


Pancreatic Cancer Rectal Cancer Rectal Tumour Circumferential Resection Margin Radiotherapy Planning 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Krengli M, et al. Target volume delineation for preoperative radiotherapy of rectal cancer: inter-observer variability and potential impact of FDG-PET/CT imaging. Technol Cancer Res Treat. 2010;9(4):393–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Buijsen J, et al. FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. Radiother Oncol. 2012;102(3):371–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Buijsen J, et al. FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiother Oncol. 2011;98(2):270–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Braendengen M, et al. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. Int J Radiat Oncol Biol Phys. 2011;81(4):e439–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Seierstad T, et al. MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiother Oncol. 2009;93(2):279–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Konski A, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(4):1123–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Dalah E, et al. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;89(3):633–40.CrossRefPubMedGoogle Scholar
  8. 8.
    MacManus M, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91(1):85–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Kantorova I, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44(11):1784–8.PubMedGoogle Scholar
  10. 10.
    Roels S, et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol. 2008;47(7):1237–48.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Clinical OncologyThe Royal Marsden NHS Foundation Trust and The Institute of Cancer ResearchLondonUK

Personalised recommendations